Cryo-Cell International Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療服務供應商行業排名57/78位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價8.50。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Cryo-Cell International Inc評分
相關信息
行業排名
57 / 78
全市場排名
285 / 4582
所屬行業
醫療服務供應商
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
持有
評級
8.500
目標均價
+86.81%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Cryo-Cell International Inc亮點
亮點風險
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
公司代碼CCEL
公司Cryo-Cell International Inc
CEOPortnoy (Mark L)
網址https://www.cryo-cell.com/
常見問題
Cryo-Cell International Inc(CCEL)的當前股價是多少?
Cryo-Cell International Inc(CCEL)的當前股價是 3.750。
Cryo-Cell International Inc 的股票代碼是什麼?
Cryo-Cell International Inc的股票代碼是CCEL。
Cryo-Cell International Inc股票的52週最高點是多少?
Cryo-Cell International Inc股票的52週最高點是8.790。
Cryo-Cell International Inc股票的52週最低點是多少?
Cryo-Cell International Inc股票的52週最低點是3.570。
Cryo-Cell International Inc的市值是多少?
Cryo-Cell International Inc的市值是30.21M。
Cryo-Cell International Inc的淨利潤是多少?
Cryo-Cell International Inc的淨利潤為402.10K。
現在Cryo-Cell International Inc(CCEL)的股票是買入、持有還是賣出?
根據分析師評級,Cryo-Cell International Inc(CCEL)的總體評級為持有,目標價格為8.500。
Cryo-Cell International Inc(CCEL)股票的每股收益(EPS TTM)是多少
Cryo-Cell International Inc(CCEL)股票的每股收益(EPS TTM)是-0.056。